Wilkinson Michelle J, Chan Katie E, Hayes Andrew J, Strauss Dirk C
Department of Academic Surgery, Sarcoma and Melanoma Unit, The Royal Marsden NHS Foundation Trust, London, UK.
Ann Surg Oncol. 2014 Jul;21(7):2144-9. doi: 10.1245/s10434-014-3618-5. Epub 2014 Mar 7.
Fibromatosis can be classified according to site of origin, namely, extraabdominal, abdominal wall, or intraabdominal. This study reports on the surgical management and long-term outcomes from a single center in the management of sporadic abdominal wall fibromatosis.
Patients who underwent surgery for abdominal wall fibromatosis between 1998 and 2013 were identified from a prospectively maintained database. A retrospective review of patient demographics, tumor characteristics, surgical outcomes, operative management, and recurrence rates was performed.
Fifty patients underwent resection of a primary sporadic abdominal wall fibromatosis; 48 were female, of whom 43 reported previous pregnancy. Twenty-seven patients (54 %) had prior abdominal surgery for other pathologies. Macroscopic clearance was achieved in all cases. The median size of tumors resected was 8 cm (range 3-15 cm). The abdominal wall defect was reconstructed with prosthetic mesh in 47 of 50 cases. No major postoperative complication was encountered. Microscopic margins were reported as clear (R0) in 21 of 50 cases. With a median follow-up of 6 years (range 1-15 years), 46 of 50 patients remain disease free, with a median disease-free survival of 5 years. Of these 46 disease-free patients, 13 had further pregnancies without complications from either the abdominal mesh repair or tumor recurrence.
For asymptomatic sporadic abdominal wall fibromatosis, observation is an accepted first-line strategy. However, in contrast to extraabdominal fibromatosis, the preferred definitive treatment is surgical resection, which is recommended as first-line therapy in symptomatic patients, selected cases when tumors are progressing, and those with tumors >7 cm.
纤维瘤病可根据起源部位进行分类,即腹外、腹壁或腹内。本研究报告了来自单一中心对散发性腹壁纤维瘤病的外科治疗及长期结果。
从一个前瞻性维护的数据库中识别出1998年至2013年间接受腹壁纤维瘤病手术的患者。对患者的人口统计学、肿瘤特征、手术结果、手术管理和复发率进行回顾性分析。
50例患者接受了原发性散发性腹壁纤维瘤病切除术;48例为女性,其中43例有过妊娠史。27例患者(54%)曾因其他疾病接受过腹部手术。所有病例均实现了肉眼下切除。切除肿瘤的中位大小为8 cm(范围3 - 15 cm)。50例中有47例用人工补片重建腹壁缺损。未出现重大术后并发症。50例中有21例报告显微镜下切缘阴性(R0)。中位随访6年(范围1 - 15年),50例患者中有46例无疾病复发,无病生存期中位值为5年。在这46例无病患者中,13例再次妊娠,未出现腹部补片修复或肿瘤复发相关并发症。
对于无症状的散发性腹壁纤维瘤病,观察是公认的一线策略。然而,与腹外纤维瘤病不同,首选的确定性治疗方法是手术切除,对于有症状的患者、肿瘤进展的特定病例以及肿瘤>7 cm的患者,建议将手术切除作为一线治疗。